Drug intelligence / Profile preview

ELI-101

Development stage: Unknown
Lead developer: Eli Radiopharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ELI-101 is a diagnostic radiopharmaceutical candidate under development by Eli Radiopharma for the imaging and diagnosis of neurological diseases. Labeled with the positron-emitting radioisotope Fluorine-18 (18F), the agent is designed for use in positron emission tomography (PET) imaging. Unlike the majority of Eli Radiopharma's pipeline, which consists of theranostic pairs developed in-house, ELI-101 is a dedicated diagnostic tool being co-developed with an undisclosed partner. It is currently in the discovery stage of development.

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on ELI-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELI-101.

Explore the full profile